

NOVO NORDISK A S
Form 6-K
November 21, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

November 20, 2017

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 2 February 2017.

Under the programme initiated 1 November 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 4.8 billion in the period from 1 November 2017 to 30 January 2018.

Since the announcement as of 13 November 2017, the following transactions have been made under the programme:

| | Number of B shares | Average purchase price | Transaction value, DKK |
|--|-------------------------------|-----------------------------------|-----------------------------------|
| Accumulated, last announcement | 2,055,000 | | 655,055,419 |
| 13 November 2017 | 260,000 | 318.20 | 82,731,864 |
| 14 November 2017 | 280,000 | 315.40 | 88,313,045 |
| 15 November 2017 | 280,000 | 313.45 | 87,766,350 |
| 16 November 2017 | 275,000 | 318.64 | 87,626,125 |
| 17 November 2017 | 275,000 | 319.61 | 87,892,243 |
| Accumulated under the programme | 3,425,000 | | 1,089,385,046 |

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 4,329 B shares in the period from 13 November 2017 to 16 November 2017. The shares in these transactions were not part of the Safe Harbour repurchase programme.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 49,416,054 B shares of DKK 0.20, corresponding to 2.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 2 February 2017. As of 17 November 2017, Novo Nordisk has repurchased a total of 48,316,831 B shares equal to a transaction value of DKK 13,289,356,074.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information

Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | | |
|-------------------------|---------------|---------------------|
| Novo Nordisk A/S | Novo Allé | Internet: |
| Investor Relations | 2880 Bagsværd | www.novonordisk.com |
| | Denmark | CVR no: |
| | | +45 4444 8888 |
| | | 24 25 67 90 |

Company announcement No 86 / 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: November 20, 2017

Lars Fruergaard Jørgensen

Chief Executive Officer